 |
29 Diseases |  |
3 Trials |
|
3 Trials |  |
104 News |  |
| 12» |
- amphetamine/dextroamphetamine ER / Generic mfg.
Mixed-Amphetamine Salts, Extended Release (Adderall XR) for Cognitive Impairment in Persons with MS (Onsite; Exhibit Hall AB) - Feb 16, 2025 - Abstract #ACTRIMSForum2025ACTRIMS_Forum_352;
Abstract is embargoed at this time.
- | amphetamine/dextroamphetamine ER / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Adderall XR and Cognitive Impairment in MS (clinicaltrials.gov) - Oct 17, 2024
P2/3, N=180, Active, not recruiting, Sponsor: Sarah Morrow
Abstract is embargoed at this time. Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Nov 2024
- | amphetamine/dextroamphetamine ER / Generic mfg.
Trial completion date, Trial primary completion date: Adderall XR and Cognitive Impairment in MS (clinicaltrials.gov) - Oct 26, 2023
P2/3, N=180, Recruiting, Sponsor: Sarah Morrow
Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Nov 2024 Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
- | amphetamine/dextroamphetamine ER / Generic mfg.
Trial completion date, Trial primary completion date: Stimulant-rTMS: Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder (clinicaltrials.gov) - Oct 2, 2023
P1, N=30, Enrolling by invitation, Sponsor: University of California, Los Angeles
Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Aug 2023 --> Mar 2024 Trial completion date: Jun 2022 --> Sep 2025 | Trial primary completion date: Jun 2022 --> Sep 2025
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change: NERF: Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder (clinicaltrials.gov) - Sep 21, 2023
P4, N=153, Completed, Sponsor: University of Cincinnati
Trial completion date: Jun 2022 --> Sep 2025 | Trial primary completion date: Jun 2022 --> Sep 2025 Active, not recruiting --> Completed | N=240 --> 153
- | methylphenidate prolonged release tablet - 12 hrs acting / Generic mfg., amphetamine/dextroamphetamine ER / Generic mfg.
Biomarker, Enrollment open, Trial completion date, Trial primary completion date: BAT: Biomarkers of ADHD Treatment Response (clinicaltrials.gov) - Sep 7, 2023
P1, N=30, Recruiting, Sponsor: Boston Children's Hospital
Active, not recruiting --> Completed | N=240 --> 153 Not yet recruiting --> Recruiting | Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: Jul 2023 --> Jul 2024
- || thyroxine / Generic mfg., bupropion / Generic mfg., amphetamine/dextroamphetamine ER / Generic mfg.
Ime over a long time prescribing there are very few meds where brand makes a difference for some people (though sometimes folks get a really wonky generic but all the other generics work fine) - synthroid, adderall XR, and Wellbutrin XR are the three exceptions I see. (Twitter) - Apr 27, 2023
- | methylphenidate prolonged release tablet - 12 hrs acting / Generic mfg., amphetamine/dextroamphetamine ER / Generic mfg.
Biomarker, New P1 trial: BAT: Biomarkers of ADHD Treatment Response (clinicaltrials.gov) - Dec 14, 2022
P1, N=30, Not yet recruiting, Sponsor: Boston Children's Hospital
- Vyvanse (lisdexamfetamine) / Shionogi, Takeda
Therapeutic Interchange Cost-savings Initiative: Lisdexamfetamine to Amphetamine/dextroamphetamine ER (Bayside A, Level 1) - Nov 12, 2022 - Abstract #ASHP2022ASHP_595;
- amphetamine/dextroamphetamine ER / Generic mfg.
Following Pediatric Bipolar Symptoms Through Developmental Transitions: New Findings and Directions () - Oct 19, 2022 - Abstract #AACAP2022AACAP_1355;
Methods Melissa DelBello, MD, will present comparisons of clinical and neural characteristics in youth who have ADHD with and without a parent with BD and healthy-comparison youth, and among youth who have ADHD with and without a parent with BD following 12 weeks of treatment with Adderall XR (dextroamphetamine/amphetamine)...Vogel-Hammen and Luby find that PBD showed continuity into adulthood and that alterations in sleep and circadian rhythm were found in adults who had BD as children. Conclusions Manpreet Singh, MD will serve as discussant and will synthesize the studies presented and challenge speakers to translate their findings into real-world application to maximize clinical utility and patient education.
- | amphetamine/dextroamphetamine ER / Generic mfg.
Journal: Posterior Reversible Encephalopathy Syndrome With Visual Disturbances in an Adolescent After Overdose With Adderall XR: A Case Report. (Pubmed Central) - Oct 4, 2022
Conclusions Manpreet Singh, MD will serve as discussant and will synthesize the studies presented and challenge speakers to translate their findings into real-world application to maximize clinical utility and patient education. No abstract available
- || amphetamine/dextroamphetamine ER / Generic mfg.
Is it me…or is #adderall not working like it used to🤷🏼♀️💊 #ADHD #ADD #FOCUS @TevaUSA #diditchange #notworking #adderallxr #AskingForAFriend (Twitter) - Sep 9, 2022
- ||| amphetamine/dextroamphetamine ER / Generic mfg.
Ah yes adderall xr not the best, but explains why speed never did to me what it did to others, possibly explains the starting smoking at 10 too, and that initially smoking made asthma better. Never been an addiction person, thankfully, a stubborn streak a mile wide helps too. (Twitter) - Aug 18, 2022
- || amphetamine/dextroamphetamine ER / Generic mfg.
@TakedaPharma I'm trying to determine if both @Amgen and @PrascoAGs produce authorized generics of Adderall XR. Pharmacy unable to order Prasco from supplier, is Amgen an option? (Twitter) - Jul 26, 2022
- | amphetamine/dextroamphetamine ER / Generic mfg.
Trial completion date, Trial primary completion date: Adderall XR and Cognitive Impairment in MS (clinicaltrials.gov) - Apr 6, 2022
P2/3, N=180, Recruiting, Sponsor: Sarah Morrow
No abstract available Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
- | NN1213 / Novo Nordisk
Enrollment closed, Trial primary completion date: NERF: Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder (clinicaltrials.gov) - Feb 28, 2022
P4, N=240, Active, not recruiting, Sponsor: University of Cincinnati
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Aug 2023 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2021 --> Apr 2022
- | Dyanavel XR (amphetamine XR) / Tris Pharma
Journal: Comparative Bioavailability of Amphetamine Extended-Release Oral Suspension and Extended-Release Mixed Amphetamine Salts. (Pubmed Central) - Dec 30, 2021
The bioavailability of a single 7.5 mL dose of AMPH EROS 2.5 mg/mL was comparable to a single 30 mg capsule dose of ER MAS. AMPH EROS (both d- and l-amphetamine) showed equivalent peak and overall exposure to ER MAS under fasted conditions.
- | amphetamine/dextroamphetamine ER / Generic mfg.
Enrollment open: Stimulant-rTMS: Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder (clinicaltrials.gov) - Sep 28, 2021
P1, N=30, Enrolling by invitation, Sponsor: University of California, Los Angeles
AMPH EROS (both d- and l-amphetamine) showed equivalent peak and overall exposure to ER MAS under fasted conditions. Not yet recruiting --> Enrolling by invitation
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: NERF: Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder (clinicaltrials.gov) - Jul 1, 2021
P4, N=240, Recruiting, Sponsor: University of Cincinnati
Not yet recruiting --> Enrolling by invitation Trial completion date: Aug 2020 --> Dec 2022 | Trial primary completion date: Aug 2020 --> Dec 2021
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: A Sequenced Behavioral and Medication Intervention for Cocaine Dependence (clinicaltrials.gov) - Jun 14, 2021
P1/2, N=145, Completed, Sponsor: New York State Psychiatric Institute
Trial completion date: Aug 2020 --> Dec 2022 | Trial primary completion date: Aug 2020 --> Dec 2021 Active, not recruiting --> Completed | Trial completion date: May 2022 --> Jan 2021 | Trial primary completion date: May 2021 --> Jan 2021
- | amphetamine/dextroamphetamine ER / Generic mfg.
Trial completion date, Trial primary completion date: Adderall XR and Cognitive Impairment in MS (clinicaltrials.gov) - Mar 23, 2021
P2/3, N=180, Recruiting, Sponsor: Sarah Morrow
Active, not recruiting --> Completed | Trial completion date: May 2022 --> Jan 2021 | Trial primary completion date: May 2021 --> Jan 2021 Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Aug 2020 --> Aug 2022
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: A Sequenced Behavioral and Medication Intervention for Cocaine Dependence (clinicaltrials.gov) - Feb 2, 2021
P1/2, N=145, Active, not recruiting, Sponsor: New York State Psychiatric Institute
Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Aug 2020 --> Aug 2022 Trial completion date: Aug 2021 --> May 2022 | Trial primary completion date: Dec 2020 --> May 2021
- || amphetamine/dextroamphetamine ER / Generic mfg.
Clinical, Journal: A Single-Dose, Two-Way Crossover, Open-Label Bioequivalence Study of an Amphetamine Extended-Release Oral Suspension in Healthy Adults. (Pubmed Central) - Nov 22, 2020
Trial completion date: Aug 2021 --> May 2022 | Trial primary completion date: Dec 2020 --> May 2021 AMP XR-OS is bioequivalent to Adderall XR in healthy adult participants.
- || amphetamine/dextroamphetamine ER / Generic mfg.
#2 is the tough one … and the most important. There is a whole practical side to this I could go into … as well as a whole philosophical tangent … but my f$&king bottle of Adderall XR turned out to be light by 24 pills this month so I just f$&king can’t right now. (Twitter) - Oct 28, 2020
- | NN1213 / Novo Nordisk
Trial primary completion date: A Sequenced Behavioral and Medication Intervention for Cocaine Dependence (clinicaltrials.gov) - Sep 11, 2020
P1/2, N=145, Active, not recruiting, Sponsor: New York State Psychiatric Institute
AMP XR-OS is bioequivalent to Adderall XR in healthy adult participants. Trial primary completion date: Aug 2020 --> Dec 2020
- | amphetamine/dextroamphetamine ER / Generic mfg.
New P1 trial: Stimulant-rTMS: Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder (clinicaltrials.gov) - Aug 10, 2020
P1, N=30, Not yet recruiting, Sponsor: University of California, Los Angeles
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: A Sequenced Behavioral and Medication Intervention for Cocaine Dependence (clinicaltrials.gov) - Jun 16, 2020
P1/2, N=145, Active, not recruiting, Sponsor: New York State Psychiatric Institute
Trial primary completion date: Aug 2020 --> Dec 2020 Trial completion date: May 2020 --> Aug 2021 | Trial primary completion date: May 2020 --> Aug 2020
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change: Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder (clinicaltrials.gov) - Jun 16, 2020
P2/3, N=33, Completed, Sponsor: New York State Psychiatric Institute
Trial completion date: May 2020 --> Aug 2021 | Trial primary completion date: May 2020 --> Aug 2020 Recruiting --> Completed | N=50 --> 33
- | NN1213 / Novo Nordisk
Enrollment closed: A Sequenced Behavioral and Medication Intervention for Cocaine Dependence (clinicaltrials.gov) - Mar 5, 2020
P1/2, N=145, Active, not recruiting, Sponsor: New York State Psychiatric Institute
Recruiting --> Completed | N=50 --> 33 Recruiting --> Active, not recruiting
- aripiprazole / Generic mfg., lorazepam / Generic mfg.
[VIRTUAL] Lorazepam-Induced Urinary Urgency (All Screens in Poster Area) - Feb 20, 2020 - Abstract #EPA2020EPA_2233;
This case reports lorazepam-induced urinary urgency resulting in treatment non-adherence with delayed reporting to the clinician. Potential benzodiazepine-induced urinary urgency should be a clinical consideration.
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder (clinicaltrials.gov) - Feb 7, 2020
P2/3, N=50, Recruiting, Sponsor: New York State Psychiatric Institute
Potential benzodiazepine-induced urinary urgency should be a clinical consideration. Trial completion date: Jan 2020 --> Jun 2020 | Trial primary completion date: Jan 2020 --> Jun 2020
- Dyanavel XR (amphetamine XR) / Tris Pharma
Comparative Bioavailability of Amphetamine Extended-Release Oral Suspension and Extended-Release Mixed Amphetamine Salts (Exhibit Hall C) - Dec 12, 2019 - Abstract #APSARD2020APSARD_22;
The bioavailability of a single 7.5 mL dose of AMPH EROS 2.5 mg/mL was comparable to a single 30 mg capsule dose of ER MAS. AMPH EROS (both d- and l-amphetamine) showed equivalent peak and overall exposure to ER MAS under fasted conditions.
- ||| methylphenidate extended release tablet / generics, amphetamine/dextroamphetamine ER / generics
Pricing: and now cvscaremark is going to start mandating BRAND NAME concerta, adderall xr and advair - $600-1000 price difference between brand and generic on 2 of the 3. I haven't used brand of concerta in my pharmacy in over 5 years.... (Twitter) - Nov 19, 2019
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: A Sequenced Behavioral and Medication Intervention for Cocaine Dependence (clinicaltrials.gov) - Oct 10, 2019
P1/2, N=155, Recruiting, Sponsor: New York State Psychiatric Institute
AMPH EROS (both d- and l-amphetamine) showed equivalent peak and overall exposure to ER MAS under fasted conditions. Trial completion date: Nov 2019 --> Apr 2020 | Trial primary completion date: Nov 2019 --> Apr 2020
- ||| Vyvanse (lisdexamfetamine) / Shionogi, Takeda
Reimbursement: @CVSHealth is the worst one because our prescription insurance runs through them amd my household's scripts are multiple and some are very expensive (ex: husband's 20 mg dose of adderall XR 2x a day, daughter's Vyvanse). I literally can't boycott them. (Twitter) - May 17, 2019
- | NN1213 / Novo Nordisk
Trial primary completion date: A Sequenced Behavioral and Medication Intervention for Cocaine Dependence (clinicaltrials.gov) - Apr 23, 2019
P1/2, N=155, Recruiting, Sponsor: New York State Psychiatric Institute
Trial completion date: Nov 2019 --> Apr 2020 | Trial primary completion date: Nov 2019 --> Apr 2020 Trial primary completion date: Mar 2019 --> Nov 2019
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder (clinicaltrials.gov) - Apr 23, 2019
P2/3, N=50, Recruiting, Sponsor: New York State Psychiatric Institute
Trial primary completion date: Mar 2019 --> Nov 2019 Trial completion date: Sep 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019
- | amphetamine/dextroamphetamine ER / Generic mfg.
Trial completion date, Trial primary completion date: Adderall XR and Cognitive Impairment in MS (clinicaltrials.gov) - Mar 22, 2019
P2/3, N=180, Recruiting, Sponsor: Sarah Morrow
Trial completion date: Sep 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Aug 2019 --> Aug 2020
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder (clinicaltrials.gov) - Aug 15, 2018
P=N/A, N=200, Active, not recruiting, Sponsor: Lily Hechtman
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Aug 2019 --> Aug 2020 Trial completion date: Oct 2017 --> Oct 2018 | Trial primary completion date: Oct 2017 --> Oct 2018
- | NN1213 / Novo Nordisk, Intuniv (guanfacine XR) / Shionogi, Takeda
Enrollment closed, Trial completion date, Trial primary completion date: The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Aug 15, 2018
P=N/A, N=70, Active, not recruiting, Sponsor: McGill University Health Center
Trial completion date: Oct 2017 --> Oct 2018 | Trial primary completion date: Oct 2017 --> Oct 2018 Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018
- | amphetamine/dextroamphetamine ER / Generic mfg.
Trial primary completion date: NERF: Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder (clinicaltrials.gov) - Apr 13, 2018
P4, N=240, Recruiting, Sponsor: University of Cincinnati
Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018 Trial primary completion date: Aug 2019 --> Aug 2020
- | amphetamine/dextroamphetamine ER / Generic mfg.
Trial completion date, Trial primary completion date: Adderall XR and Cognitive Impairment in MS (clinicaltrials.gov) - Mar 21, 2018
P2/3, N=180, Recruiting, Sponsor: Sarah Morrow
Trial primary completion date: Aug 2019 --> Aug 2020 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Apr 2018 --> Aug 2019
- | amphetamine/dextroamphetamine ER / Generic mfg.
Trial completion date, Trial primary completion date: A Sequenced Behavioral and Medication Intervention for Cocaine Dependence (clinicaltrials.gov) - Mar 13, 2018
P1/2, N=155, Recruiting, Sponsor: New York State Psychiatric Institute
Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Apr 2018 --> Aug 2019 Trial completion date: Oct 2018 --> Oct 2019 | Trial primary completion date: Mar 2018 --> Mar 2019
- | lisdexamfetamine / Generic mfg.
Trial primary completion date: Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder (clinicaltrials.gov) - Aug 30, 2017
P=N/A, N=200, Active, not recruiting, Sponsor: Lily Hechtman
Trial completion date: Oct 2018 --> Oct 2019 | Trial primary completion date: Mar 2018 --> Mar 2019 Trial primary completion date: Jun 2017 --> Oct 2017
- | lisdexamfetamine / Generic mfg., Intuniv (guanfacine XR) / Shionogi, Takeda
Trial primary completion date: The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD) (clinicaltrials.gov) - Aug 30, 2017
P=N/A, N=70, Recruiting, Sponsor: McGill University Health Center
Trial primary completion date: Jun 2017 --> Oct 2017 Trial primary completion date: Jun 2017 --> Jun 2018
- | lisdexamfetamine / Generic mfg.
Trial primary completion date: Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=200, Active, not recruiting, Sponsor: Lily Hechtman
Trial primary completion date: Jun 2017 --> Jun 2018 Trial primary completion date: Dec 2016 --> Jun 2017
- | amphetamine/dextroamphetamine ER / Generic mfg.
Enrollment open: Adderall XR and Cognitive Impairment in MS (clinicaltrials.gov) - Dec 29, 2016
P2/3, N=180, Recruiting, Sponsor: Sarah Morrow
Trial primary completion date: Dec 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- lisdexamfetamine / Generic mfg.
Trial primary completion date: Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder (clinicaltrials.gov) - Sep 14, 2016
P=N/A, N=200, Active, not recruiting, Sponsor: Lily Hechtman
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2016 --> Dec 2016
- amphetamine/dextroamphetamine ER / Generic mfg.
Enrollment open: Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder (clinicaltrials.gov) - Sep 8, 2016
P2/3, N=50, Recruiting, Sponsor: New York State Psychiatric Institute
Trial primary completion date: Jun 2016 --> Dec 2016 Not yet recruiting --> Recruiting